Clinical Trial Update: Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bexarotene and fenretinide as add-on therapy to antipsychotics in schizophrenia and schizoaffective disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Bexarotene (Bexarotene)
• Fenretinide (fenretinide)

Snippet

Sponsor: Beersheva Mental Health Center | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: WITHDRAWN